Event-free and overall survival for all patients (n = 320) and patients without ALK-positive ALCL (n = 242) according to IPI factors (Cox modeling)
| . | RR . | EFS . | P . | RR . | OS . | P . |
|---|---|---|---|---|---|---|
| 95% CI . | 95% CI . | |||||
| All | ||||||
| Age > 60 y | 1.8 | (1.3; 2.5) | < .001 | 2.2 | (1.5; 3.2) | < .001 |
| LDH > UNV | 1.6 | (1.1; 2.3) | .008 | 2.1 | (1.4; 3.1) | .001 |
| ECOG > 1 | 1.6 | (1.1; 2.4) | .018 | 1.5 | (0.9; 2.3) | .098 |
| Stage III/IV | 1.1 | (0.8; 1.6) | .488 | 1.2 | (0.8; 1.8) | .407 |
| Extranodal disease > 1 | 1.6 | (1.1; 2.4) | .011 | 1.1 | (0.7; 1.7) | .736 |
| Without ALK+ | ||||||
| Age > 60 y | 1.5 | (1.1; 2.2) | .016 | 1.7 | (1.2; 2.5) | .007 |
| LDH > UNV | 1.5 | (1.0; 2.2) | .041 | 1.8 | (1.2; 2.8) | .008 |
| ECOG > 1 | 1.6 | (1.0; 2.4) | .040 | 1.5 | (1.0; 2.4) | .076 |
| Stage III/IV | 1.3 | (0.9; 1.9) | .206 | 1.3 | (0.8; 2.1) | .218 |
| Extranodal disease > 1 | 1.7 | (1.1; 2.5) | .010 | 1.1 | (0.7; 1.8) | 0 |
| . | RR . | EFS . | P . | RR . | OS . | P . |
|---|---|---|---|---|---|---|
| 95% CI . | 95% CI . | |||||
| All | ||||||
| Age > 60 y | 1.8 | (1.3; 2.5) | < .001 | 2.2 | (1.5; 3.2) | < .001 |
| LDH > UNV | 1.6 | (1.1; 2.3) | .008 | 2.1 | (1.4; 3.1) | .001 |
| ECOG > 1 | 1.6 | (1.1; 2.4) | .018 | 1.5 | (0.9; 2.3) | .098 |
| Stage III/IV | 1.1 | (0.8; 1.6) | .488 | 1.2 | (0.8; 1.8) | .407 |
| Extranodal disease > 1 | 1.6 | (1.1; 2.4) | .011 | 1.1 | (0.7; 1.7) | .736 |
| Without ALK+ | ||||||
| Age > 60 y | 1.5 | (1.1; 2.2) | .016 | 1.7 | (1.2; 2.5) | .007 |
| LDH > UNV | 1.5 | (1.0; 2.2) | .041 | 1.8 | (1.2; 2.8) | .008 |
| ECOG > 1 | 1.6 | (1.0; 2.4) | .040 | 1.5 | (1.0; 2.4) | .076 |
| Stage III/IV | 1.3 | (0.9; 1.9) | .206 | 1.3 | (0.8; 2.1) | .218 |
| Extranodal disease > 1 | 1.7 | (1.1; 2.5) | .010 | 1.1 | (0.7; 1.8) | 0 |
ECOG indicates Eastern Cooperative Oncology Group.